证券代码：301393 证券简称：昊帆生物 公告编号：2024-029 截至 2024 年 4 月 30 日，公司通过回购专用证券账户以集中竞价交易方式累 计回购公司股份 715,048 股，占公司目前总股本的 0.66%，最高成交价为 51.50 元/股，最低成交价为 36.77 元/股，成交总金额为 30,181,482.68 元（不含交易费 用）。公司回购股份的实施符合相关法律、法规、规范性文件及公司股份回购方 案的规定。 二、其他说明 公司回购股份的时间、回购股份数量及集中竞价交易的委托时段等符合《深 圳证券交易所上市公司自律监管指引第 9 号——回购股份》的相关规定。 1、公司未在下列期间回购公司股票： （1）自可能对本公司证券及其衍生品种交易价格产生重大影响的重大事项 发生之日或者在决策过程中，至依法披露之日内； 苏州昊帆生物股份有限公司 关于股份回购进展情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 苏州昊帆生物股份有限公司（以下简称"公司"）于 2024 年 2 月 5 日召开第 三届董事会第十二次会议及第三届监事会第十二次会议，审 ...

Financial Performance - Revenue for Q1 2024 was ¥91,229,728.71, a decrease of 27.14% compared to ¥125,210,000.82 in the same period last year[5] - Net profit attributable to shareholders was ¥29,828,839.74, down 17.80% from ¥36,288,001.96 year-over-year[5] - Net profit excluding non-recurring items was ¥25,769,764.03, reflecting a decline of 24.12% from ¥33,960,792.95 in the previous year[5] - Basic and diluted earnings per share decreased to ¥0.28, down 37.78% from ¥0.45 in the prior year[5] - Total operating revenue for Q1 2024 was CNY 91,229,728.71, a decrease of 27.1% compared to CNY 125,210,000.82 in the same period last year[24] - Net profit for Q1 2024 was CNY 29,828,839.74, a decline of 17.7% from CNY 36,288,001.96 in Q1 2023[25] Cash Flow and Liquidity - Operating cash flow improved significantly, with a net cash flow from operating activities of ¥23,295,794.97, compared to a negative cash flow of ¥11,994,516.75 in the same quarter last year, marking a 294.22% increase[5] - Cash and cash equivalents at the end of the reporting period amount to 1,734,899,973.95 RMB, slightly down from 1,739,510,856.63 RMB at the beginning of the period[20] - Cash flow from investment activities was negative at -$22,411,271.01, an improvement from -$45,816,287.92 in the previous period[28] - Cash flow from financing activities also showed a negative trend at -$9,629,027.59, compared to -$658,849.75 previously[28] - The ending cash and cash equivalents balance was $1,246,675,971.66, a decrease from $1,255,236,454.77 at the beginning of the period[28] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥2,312,149,453.18, a slight increase of 1.10% from ¥2,286,941,939.28 at the end of the previous year[5] - Total liabilities for Q1 2024 were CNY 79,605,794.21, up from CNY 75,077,619.91 in Q1 2023[22] - Cash and cash equivalents increased to CNY 1,981,489,807.37 from CNY 1,964,007,891.97 year-over-year[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 12,434[12] - The largest shareholder, Zhu Yong, holds 47.40% of shares, totaling 51,192,000 shares[12] - The company plans to repurchase shares with a total amount not less than 30 million RMB and not exceeding 60 million RMB, with a maximum repurchase price of 60 RMB per share[17] - As of March 31, 2024, the company has repurchased 200,000 shares, accounting for 0.19% of the total share capital, with a total transaction amount of 9,432,971 RMB[18] Research and Development - Research and development expenses surged by 122.67% to ¥10,389,895.99, primarily due to an increase in R&D personnel[9] - Research and development expenses for Q1 2024 were CNY 10,389,895.99, significantly higher than CNY 4,665,960.48 in Q1 2023, indicating increased investment in innovation[24] Financial Management - Interest income skyrocketed by 8,561.83% to ¥12,439,672.85, attributed to cash management of idle raised funds[9] - The company reported a financial income of CNY 12,439,672.85 in Q1 2024, compared to CNY 143,614.88 in the same period last year, reflecting improved financial management[25] - The company received government subsidies totaling ¥4,500,000.00, contributing positively to its financial performance[7] Market Strategy - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[24]

证券代码：301393 证券简称：昊帆生物 公告编号：2024-027 苏州昊帆生物股份有限公司 4、会议召开的日期、时间： （1）现场会议召开日期：2024 年 5 月 10 日（星期五）下午 2 时 30 分 （2）互联网投票时间： ①通过深圳证券交易所交易系统进行网络投票的具体时间为：2024 年 5 月 10 日 9:15—9:25，9:30—11:30，13:00—15:00; 关于召开 2023 年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 苏州昊帆生物股份有限公司于 2024 年 4 月 9 日在中国证监会指定的创业板 信息披露网站巨潮资讯网（www.cninfo.com.cn）上披露了《关于召开 2023 年度 股东大会的通知》（公告编号：2024-021）。本次股东大会采用现场表决与网络投 票相结合的方式召开，现将本次股东大会的有关事宜提示如下： 一、召开会议的基本情况 1、股东大会届次：2023 年度股东大会。 2、股东大会的召集人：苏州昊帆生物股份有限公司（以下简称"公司"）第三 届董事会第十三次会议决议提请召 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [18] Core Insights - The company's core products have strong market competitiveness, and the construction of its own production capacity is progressing rapidly, which will empower long-term development [2] - In 2023, the company achieved operating revenue of 389 million yuan, a year-on-year decline of 13.11%, and a net profit attributable to the parent company of 99 million yuan, down 23.50% year-on-year [8][19] - The company is focusing on the peptide synthesis reagent segment, with the ability to mass-produce and stably supply over 160 products, accounting for 75% of the total [9] - The company is accelerating its own production capacity construction, with the first phase of its Anhui Haofan production base having been put into operation in August 2022, and the second phase expected to achieve trial production in February 2024 [9] Financial Performance Summary - In Q4 2023, the company achieved operating revenue of 85.16 million yuan, a year-on-year decline of 1.93% and a quarter-on-quarter decline of 8.96% [8] - The gross profit margin for Q4 was 34.32%, an increase of 1.98 percentage points quarter-on-quarter, while the net profit margin was 23.57%, up 2.01 percentage points quarter-on-quarter [8] - The company expects net profits for 2024-2026 to be 117 million, 150 million, and 189 million yuan respectively, with corresponding EPS of 1.08, 1.39, and 1.75 yuan [8][19] - The current stock price corresponds to a P/E ratio of 39.2, 30.7, and 24.3 for 2024, 2025, and 2026 respectively [8][19]

Financial Performance - Net profit for the current period is ¥98,973,754.53, a decrease of 23.5% compared to ¥129,370,943.06 in the previous period[50]. - Cash flow from operating activities for the current period is ¥87,829,868.67, down 36.6% from ¥138,673,297.82 in the previous period[50]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion in the last fiscal year, representing a growth of 15% year-over-year[119]. - Total operating revenue for 2023 was ¥388,794,947.08, a decrease of 13.1% compared to ¥447,457,811.11 in 2022[182]. - Basic and diluted earnings per share for 2023 were both ¥1.07, compared to ¥1.60 in 2022[183]. - The total equity increased to ¥2,129,084,007.67 in 2023 from ¥451,253,592.59 in 2022, showing a growth of 372%[182]. Research and Development - The company aims to develop new products, including liposome and lipid nanoparticle reagents, ionic liquids, PROTAC reagents, and nucleotide reagents, to meet customer demands and enhance its market position[27]. - The company emphasizes research and development as a priority, aiming to provide specialized chemical raw materials with higher synthesis technology barriers to support the pharmaceutical industry[28]. - The company has been granted 7 new invention patents in 2023, bringing the total to 38 patents, including 34 invention patents and 4 utility model patents[29]. - The company is investing heavily in R&D, with 150 million allocated for new technology development, aiming to enhance product efficiency and effectiveness[123]. - The company has engaged in various research projects, including over 120 published research papers and more than 30 authorized invention patents[100]. Production and Operations - The company plans to enhance production capacity and expand its product line, focusing on the construction of the Anhui Haofan production base project and potentially acquiring additional production bases[22]. - The company maintains a focus on optimizing production processes and developing new product technologies to enhance operational efficiency[28]. - The company has implemented a quality management system compliant with ISO9001 standards, ensuring stable production processes and reliable product quality[30]. - The company has a strong emphasis on sustainable development supported by its robust synthesis technology reserves[29]. Financial Position - The total current assets as of December 31, 2023, reached approximately CNY 1.96 billion, a significant increase from CNY 352.67 million at the beginning of the year, reflecting a growth of over 455%[163]. - Cash and cash equivalents amounted to CNY 1.74 billion, up from CNY 99.32 million, indicating a growth of approximately 1,754%[163]. - The company's fixed assets increased to CNY 212.35 million from CNY 116.78 million, representing an increase of about 81.8%[166]. - The total liabilities amounted to ¥46,461,176.10 in 2023, compared to ¥103,735,086.64 in 2022, indicating a significant reduction[182]. Market Strategy - The company plans to expand its market presence and enhance its product offerings through ongoing research and development initiatives[100]. - Market expansion plans include entering two new international markets, projected to increase market share by 5%[126]. - The company is considering strategic acquisitions to bolster its market position, with a budget of up to 300 million for potential targets[126]. - Future guidance indicates a focus on increasing operational efficiency and expanding into new markets, with specific targets to be outlined in subsequent reports[153]. Corporate Governance - The company has established a structured and efficient corporate governance framework, enhancing operational efficiency through clear responsibilities among various governance bodies[31]. - The company has engaged in discussions to enhance decision-making processes, ensuring the interests of minority shareholders are considered[63]. - The board of directors did not raise any objections regarding company matters during the reporting period, indicating a unified leadership approach[115]. - The company has established a compensation and assessment committee to determine the remuneration of directors and senior management based on internal policies[103]. Shareholder Information - The company’s major shareholder remains unchanged during the reporting period, with no new changes in control[82]. - The actual controller, Zhu Yong, holds a 48.04% stake in the company, ensuring significant influence over corporate decisions[149]. - The company has not conducted any repurchase transactions among the top ten shareholders during the reporting period[84].

苏州昊帆生物股份有限公司 审计报告 中天运[2024]审字第 90047 号 中天运会计师事务所（特殊普通合伙） JONTEN CERTIFIED PUBLIC ACCOUNTANTS LLP 中天运会计师事务所（特殊普通合伙）JONTEN CPAS | | | | 1、 | 审计报告 | ………………………………………………1 | | --- | --- | --- | | 2、 | 合并资产负债表 | ………………………………………5 | | 3、 | 母公司资产负表 | ………………………………………7 | | 4、 | 合并利润表 | ……………………………………………9 | | 5、 | 母公司利润表 | …………………………………………10 | | 6、 | 合并现金流量表 | ………………………………………11 | | 7、 | 母公司现金流量表 | ……………………………………12 | | 8、 | 合并所有者权益变动表 | ………………………………13 | | 9、 | 母公司所有者权益变动表 | ……………………………15 | | | 10、财务报表附注 | ……………………………………… ...

苏州昊帆生物股份有限公司 董事会战略委员会实施细则 第一章 总则 第一条 为适应公司战略发展需要，增强公司核心竞争力，确定公司发展规划， 健全投资决策程序，加强决策科学性，提高重大投资决策的效益和决策的质量，完 善公司的治理结构，根据《中华人民共和国公司法》（以下简称"《公司法》"） 《上市公司治理准则》《上市公司独立董事管理办法》等法律、法规、规范性文件 及《苏州昊帆生物股份有限公司章程》（以下简称"《公司章程》"）的规定，公 司特设立董事会战略委员会，并制定本细则。 第二条 董事会战略委员会是董事会设立的专门工作机构，主要负责对公司 长期发展战略和重大投资决策进行研究并提出建议。 第二章 人员组成 第三条 战略委员会成员由 3 名董事组成，其中至少包括 1 名独立董事。 第四条 战略委员会委员由董事长、二分之一以上独立董事或者全体董事的 三分之一提名，并由董事会选举产生。 1 （四）具备良好的道德品行，具有人力资源管理、企业管理、财务、法律等相 关专业知识或工作背景； （五）符合有关法律、法规或《公司章程》规定的其他条件。 第七条 不符合前条规定的任职条件的人员不得当选为战略委员会委员。战 略委员会委员在 ...

苏州吴帆生物股份有限公司 内部控制签证报告 专 项 报 告 中天运[2024]核字第 90052 号 中天运会计师事务所 (特殊普通合伙 ) JONTEN CERTIFIED PUBLIC ACCOUNTANTS (LIMITED LIABILITY PARTNERSHIP) 目 录 | 一、内部控制鉴证报告 · | | --- | | 二、关于公司内部控制有效性的自我评价报告 ·································································· 3 | 苏州昊帆生物股份有限公司全体股东: 我们审核了后附的苏州昊帆生物股份有限公司(以下简称吴帆生物)管理层按 照《企业内部控制基本规范》及相关规定对 2023年 12月 31 日与财务报告相关的内 部控制有效性作出的认定。 一、管理层的责任 昊帆生物管理层的责任是建立健全内部控制并保持其有效性,同时按照《企业 内部控制基本规范》及相关规定对 2023年12月 31 日与财务报告相关的内部控制有 效性作出认定,并对上述认定负责。 二、注册会计师的责任 我们的责任是在实施鉴证工作的基础上对与财务报告相关 ...

证券代码：301393 证券简称：昊帆生物 公告编号：2024-025 苏州昊帆生物股份有限公司 关于 2024 年中期分红安排的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 公司拟于 2024 年第三季度结合未分配利润与当期业绩进行分红，以实施权 益分派股权登记日登记的公司股份总数扣减公司回购专用证券账户中的股份为 基数，派发现金红利总金额不超过相应期间归属于上市公司股东净利润的 20%。 中期分红的前提条件为：1、公司在当期盈利、累计未分配利润为正；2、公 司现金流可以满足正常经营和持续发展的要求。 为简化分红程序，董事会拟提请股东大会批准授权，董事会根据股东大会决 议在符合利润分配的条件下制定具体的中期分红方案。 苏州昊帆生物股份有限公司（以下简称"公司"）根据中国证监会《上市公 司章程指引（2023 年修订）》《上市公司监管指引第 3 号—上市公司现金分红（2023 年修订）》和深圳证券交易所《上市公司自律监管指引第 2 号——创业板上市公 司规范运作（2023 年 12 月修订）》，为进一步提高分红频次，增强投资者回报水 平，结合公司实际情况 ...

苏州昊帆生物股份有限公司 2023 年度独立董事述职报告 本人张兆国，作为苏州昊帆生物股份有限公司（以下简称"公司"）的独立董 事（已离任），在任职期间严格按照《公司法》《上市公司治理准则》和《上市公 司独立董事管理办法》等法律法规以及《公司章程》的规定，本着客观、公正、 独立的原则，勤勉尽责，积极发挥独立董事作用，维护公司整体利益和全体股东 尤其是中小股东的合法权益。现将 2023 年度履职情况总结如下： 一、基本情况 张兆国，1968 年 11 月出生，中国国籍，无境外永久居留权，博士研究生学 历。曾任上海交通大学分析测试中心主任、国家转化医学重大基础设施（上海） 公共仪器平台主任。2021 年 6 月至 2023 年 8 月任公司独立董事。 2023 年 7 月，本人向公司董事会递交了辞职申请。2023 年 8 月，公司召开 2023 年第一次临时股东大会，补选余家会先生为公司第三届董事会独立董事， 本人不再担任公司独立董事。 报告期内，本人作为公司独立董事符合《上市公司独立董事管理办法》第六 条规定的独立性要求，不存在影响独立性的情况。 二、2023 年度履职概况 本人在任职期间内积极参加了公司召开的 ...